A. Sarris

发表

Expression of p27Kip1 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma

T. McDonnell, G. Rassidakis, L. Medeiros, 2003 .

Expression of p27 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma

T. McDonnell, G. Rassidakis, L. Medeiros, 2003 .

Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma.

T. McDonnell, G. Rassidakis, L. Medeiros, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.

A. López-Guillermo, F. Cavalli, H. Gómez, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.

Terry L. Smith, Maria A. Rodriguez, P. Mclaughlin, 2002, Blood.

Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐Hodgkin lymphomas

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2013, British journal of haematology.

Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.

Terry L. Smith, Maria A. Rodriguez, P. Mclaughlin, 2003, Oncology reports.

Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study.

D. Moore, F. Cabanillas, A. Sarris, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma.

G. Rassidakis, L. Medeiros, M. Herling, 2006, Blood.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors.

T. McDonnell, F. Cabanillas, G. Rassidakis, 2002, The American journal of pathology.

Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria.

G. Rassidakis, L. Medeiros, M. Herling, 2004, Human pathology.

Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, A. Sarris, 1998, Leukemia & lymphoma.

Paclitaxel plus high‐dose cyclosphosphamide with G‐CSF support in patients with relapsed and refractory aggressive non‐Hodgkin's lymphoma

P. Mclaughlin, F. Cabanillas, A. Younes, 1998, British journal of haematology.

Phase II Study of Paclitaxel in Combination with Mitoxantrone and Ifosfamide/Mesna for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma after Failure to Cytarabine/Cisplatin Combination

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Investigational New Drugs.

Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.

J. Cox, F. Cabanillas, A. Younes, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Leukemia & lymphoma.

Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.

F. Cavalli, P. Roy, M. Gospodarowicz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease

Maria A. Rodriguez, L. Levy, E. Atkinson, 2004, American journal of clinical oncology.

Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.

T. McDonnell, G. Rassidakis, L. Medeiros, 2001, The American journal of pathology.

Anaplastic Lymphoma Kinase (ALK) is not Expressed in Hodgkin's Disease: Results with ALK-11 Antibody in 327 Untreated Patients

F. Cabanillas, G. Rassidakis, L. Medeiros, 2001, Leukemia & lymphoma.

Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.

M. Waasdorp, A. Sarris, R. Luthra, 1998, Hematopathology and molecular hematology.

Real-time 5'-->3' exonuclease-based PCR assay for detection of the t(11;14)(q13;q32).

L. Medeiros, A. Sarris, A. Paladugu, 1999, American journal of clinical pathology.

Novel 5' exonuclease-based real-time PCR assay for the detection of t(14;18)(q32;q21) in patients with follicular lymphoma.

A. Sarris, R. Luthra, R. Luthra, 1998, The American journal of pathology.

Technical Advance Novel 5 9 Exonuclease-Based Real-Time PCR Assay for the Detection of t(14;18)(q32;q21) in Patients with Follicular Lymphoma

F. Cabanillas, A. Sarris, R. Luthra, 1998 .

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2000, Seminars in oncology.

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.

P. Mclaughlin, F. Cabanillas, A. Younes, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD4− CD8− `Double-Negative' Cutaneous T-Cell Lymphomas Share Common Histologic Features and an Aggressive Clinical Course

L. Medeiros, A. Sarris, F. Vega, 2002, The American journal of surgical pathology.

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-Hodgkin's Lymphoma Involving the Gynecologic Tract: A Review of 88 Cases

G. Fuller, M. Deavers, L. Medeiros, 2001, Advances in anatomic pathology.

Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia

Susan O'Brien, Jorge Cortes, Guillermo Garcia-Manero, 2006, Cancer.

Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma.

F. Cabanillas, G. Rassidakis, L. Medeiros, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Real-Time Polymerase Chain Reaction of Genomic DNA for Quantitation of t(14;18)

F. Cabanillas, A. Sarris, Apostolia M Tsimberidou, 2003 .

Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.

P. Mclaughlin, F. Cabanillas, G. Rassidakis, 2002, Seminars in oncology.

Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.

P. Mclaughlin, F. Cabanillas, A. Sarris, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Human interferon-inducible protein 10: expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors

J. Krueger, H. Broxmeyer, A. Sarris, 1993, The Journal of experimental medicine.

Macrophage-stimulating protein, a ligand for the RON receptor protein tyrosine kinase, suppresses myeloid progenitor cell proliferation and synergizes with vascular endothelial cell growth factor and members of the chemokine family

D. Donner, E. Leonard, A. Sarris, 1996, Annals of Hematology.

The sialoglycoproteins of murine erythrocyte ghosts. A modified periodic acid-Schiff stain procedure staining nonsubstituted and O-acetylated sialyl residues on glycopeptides.

G. Palade, A. Sarris, 1979, The Journal of biological chemistry.

Human recombinant interferon-inducible protein-10 inhibits the proliferation of normal and acute myelogenous leukemia progenitors.

Z. Estrov, A. Deisseroth, M. Talpaz, 1996, Leukemia.

Immunofluorescent detection of erythrocyte sialoglycoprotein antigens on murine erythroid cells

G. Palade, A. Sarris, 1982, The Journal of cell biology.

Isolation and partial characterization of the sialoglycoprotein fraction of murine erythrocyte ghosts

G. Palade, A. Sarris, 1982, The Journal of cell biology.

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

P. Mclaughlin, J. Manning, F. Cabanillas, 2000, Bone Marrow Transplantation.

IMMUNOFLUORESCENT LOCALIZATION AND IMMUNOCHEMICAL DETERMINATION OF CYCLOPHILIN‐A WITH SPECIFIC RABBIT ANTISERA

A. Sarris, M. Harding, D. Aftab, 1992, Transplantation.

Quantitative Real-Time Polymerase Chain Reaction for Detection of Circulating Cells with T(14;18) in Volunteer Blood Donors and Patients with Follicular Lymphoma

P. Mclaughlin, F. Cabanillas, A. Tsimberidou, 2002, Leukemia & lymphoma.

Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (HyperCVXD) Regimen in Richter's Syndrome

H. Kantarjian, J. Cortes, M. Keating, 2001, Leukemia & lymphoma.

Protein aggregation mediated by cysteine oxidation during the stacking phase of discontinuous buffer SDS-PAGE.

A. Sarris, N. Karasavvas, M. Crow, 2001, BioTechniques.

Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3.

F. Cabanillas, A. Younes, A. Sarris, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel activity for the treatment of non‐Hodgkin's lymphoma: final report of a phase II trial

R. Kurzrock, P. Mclaughlin, L. North, 1997, British journal of haematology.

MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures.

A. Sarris, J. Cashman, A. Eaves, 1998, Blood.

Diacridines - double intercalators as chemotherapeutic agents.

A. Sarris, R. Fico, E. Canellakis, 1976, Biochemical pharmacology.

The mechanism of inhibition of bacteriophage T7 RNA synthesis by acridines, diacridines and actinomycin D.

A. Sarris, E. Canellakis, E. G. Niles, 1977, Biochimica et biophysica acta.

Clinical and Preclinical Pharmacology of Liposomal Vincristine

F. Cabanillas, M. Bally, L. Mayer, 2000 .

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy

K. Kliche, G. Bonadonna, F. Cabanillas, 2004, Leukemia & lymphoma.

Tumor Necrosis Factor-α and Interferon-γ, but not HTLV-I Tax, are Likely Factors in the Epidermotropism of Cutaneous T-Cell Lymphoma via Induction of Interferon-Inducible Protein-10

F. Cabanillas, A. Sarris, B. Gansbacher, 1998 .

Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy.

A. Sarris, D. Daliani, D. Gershenson, 1997, Gynecologic oncology.

BCL‐2 family proteins in peripheral T‐cell lymphomas: correlation with tumour apoptosis and proliferation

T. McDonnell, L. Jeffrey Medeiros, G. Rassidakis, 2003, The Journal of pathology.

Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.

F. Cabanillas, L. Medeiros, A. Sarris, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Human recombinant interferon-inducible protein-10: intact disulfide bridges are not required for inhibition of hematopoietic progenitors and chemotaxis of T lymphocytes and monocytes.

D. Taub, H. Broxmeyer, A. Sarris, 2001, Journal of hematotherapy & stem cell research.

Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy.

P. Mclaughlin, F. Cabanillas, J. Cox, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary C utaneous N on-Hodgkin's L ymphoma o f A nn A rbor Stage I : P referential C utaneous R elapses b ut H igh C ure Rate W ith D oxorubicin-Base d T herapy

P. Mclaughlin, J. Cox, F. Cabanillas, 2001 .

BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome.

T. McDonnell, G. Bonadonna, F. Cabanillas, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Lymphomas The Clinical Significance of Molecular Response in Indolent Follicular

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 2013 .

Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 1999, Blood.

The clinical significance of molecular response in indolent follicular lymphomas.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 1998, Blood.

ABVD or equivalent regimens Hodgkin disease predicts a poorer prognosis in patients treated with BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical

T. McDonnell, G. Bonadonna, F. Cabanillas, 2013 .

Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome.

K. Kliche, G. Bonadonna, F. Cabanillas, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression of Epstein-Barr Virus Latent Membrane Protein-1 in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin ’ s Lymphoma : Associations with Presenting Features , Serum Interleukin 10 Levels , and Clinical Outcome 1

K. Kliche, G. Bonadonna, F. Cabanillas, 2003 .

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens.

T. McDonnell, G. Bonadonna, F. Cabanillas, 2002, Blood.

CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome.

G. Bonadonna, P. Mclaughlin, F. Cabanillas, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

P. Mclaughlin, J. Cox, F. Cabanillas, 1998, Blood.

Cyclosporine treatment of refractory T‐cell lymphomas

W. Hait, A. Sarris, B. Saidman, 1993, Cancer.

lymphoma alternating triple therapy (ATT) regimen in patients with stage IV indolent Fludarabine, mitoxantrone, dexamethasone (FND) compared with an

P. Mclaughlin, F. Cabanillas, A. Tsimberidou, 2013 .

Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma.

C. Kittas, G. Rassidakis, M. Angelopoulou, 2001, Haematologica.

Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis

M. Federico, F. Cabanillas, G. Pangalis, 2006, European journal of haematology.

Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice

K. Cornetta, H. Broxmeyer, A. Sarris, 1995, Annals of Hematology.

Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial

Jeffrey E. Lee, R. Winn, Yu Shen, 1999, Annals of Internal Medicine.

Hodgkin's Disease in Patients Infected with Human Immunodeficiency Virus: Frequency, Presentation and Clinical Outcome

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Leukemia & lymphoma.

T7 RNA polymerase: promoter structure and polymerase binding.

A. Sarris, J. Coleman, J. L. Oakley, 1979, Biochemistry.

Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Leukemia & lymphoma.

Prospective Management of Primary Testicular Lymphoma (PTL) with Doxorubicin-Based Chemotherapy, Prophylactic Intrathecal (IT) Methotrexate and Radiotherapy (RT), but without Rituximab: Results from IELSG.

F. Cavalli, M. Gospodarowicz, G. Rassidakis, 2006 .

Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?

F. Cabanillas, L. Medeiros, A. Sarris, 2001, Clinical lymphoma.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin's Disease

P. Mclaughlin, F. Cabanillas, B. Andersson, 2016 .

ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease.

P. Mclaughlin, F. Cabanillas, B. Andersson, 1999, Blood.

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

P. Mclaughlin, F. Cabanillas, A. Younes, 1994, Investigational New Drugs.

P. Mclaughlin, F. Cabanillas, G. Rassidakis, 2002, Seminars in oncology.

Paclitaxel (Taxol) for the treatment of lymphoma.

L. North, F. Cabanillas, A. Younes, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2003, Cancer.

An elevated serum beta‐2‐microglobulin level is an adverse prognostic factor for overall survival in patients with early‐stage Hodgkin disease

S. Tucker, J. Cox, F. Cabanillas, 2002, Cancer.

Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients.

F. Cabanillas, A. Sarris, F. Hagemeister, 1998, Leukemia & lymphoma.

Interferon-inducible Protein 10 and Macrophage Inflammatory Protein-1α Inhibit Growth Factor Stimulation of Raf-1 Kinase Activity and Protein Synthesis in a Human Growth Factor-dependent Hematopoietic Cell Line (*)

H. Broxmeyer, M. Marshall, A. Sarris, 1995, The Journal of Biological Chemistry.

Results of a Phase II Study of 506U78 (Nelarabine) in Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma.

A. Bleyer, F. Cabanillas, A. Sarris, 2005 .

Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.

P. Mclaughlin, L. North, F. Cabanillas, 1997, Leukemia & lymphoma.

Interferon γ and tumor necrosis factor α mRNA expression in mycosis fungoides progression [6]

K. Asadullah, H. Volk, A. Sarris, 1996 .

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2004 .

CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)

A. Rossi, M. Federico, R. Tsang, 2011, Annals of Hematology.

Prognostic factors in early-stage Hodgkin's disease.

A. Sarris, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thomas DA, Sarris AH, Cortes J, et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006;106:120–7.

J. Cortes, Deborah A. Thomas, A. Sarris, 2006 .

Detection of t(2;5)(p23;q35) translocation by long-range PCR of genomic DNA.

L. Medeiros, A. Sarris, Yunfang Jiang, 2002, Methods in molecular medicine.

Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease.

P. Mclaughlin, F. Cabanillas, A. Younes, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary parotid lymphoma: the effect of International Prognostic Index on outcome.

P. Mclaughlin, J. Cox, F. Cabanillas, 1997, Leukemia & lymphoma.

Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl.

M. Andreeff, H. Kantarjian, J. Cortes, 1996, Leukemia & lymphoma.

Recent advances in the molecular pathogenesis of lymphomas.

A. Sarris, A. Sarris, R. Ford, 1999, Current opinion in oncology.

P. Mclaughlin, F. Cabanillas, A. Tsimberidou, 2002, Seminars in oncology.

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.

K. Kliche, M. Andreeff, S. Tucker, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.

A. López-Guillermo, F. Cavalli, H. Gómez, 2006 .

Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2006 .